NCT07143240 - Tedizolid Neuropathies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

April 1, 2025

Study Completion Date

May 1, 2025

Conditions

Adult Patients Developing Optic or Peripheral NeuropathyWhile Receiving Tedizolid Therapy Between July 2019 and December 2024

Interventions

OTHER

Determine patient demographic and clinical characteristics at baseline

Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, clinical data relating to neuropathy, and tedizolid prescription modalities (dose, duration).

Trial Locations (1)

69004

HCL, Lyon

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER